ArticleMolecules (Basel, Switzerland)2019
Insight into the PTP1B Inhibitory Activity of Arylbenzofurans: An In Vitro and In Silico Study.
Article in Molecules (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Mulberrofuran A: A Multifunctional 2-Arylbenzofuran Flavonoid-Insights into Pharmacological Actions, Molecular Mechanisms, and Therapeutic Potential.Molecules (Basel, Switzerland) · 2026Review
- Galloylated Phenolics from Indian Gooseberry (ACS omega · 2026Article
- Comprehensive overview of different medicinal parts fromFrontiers in pharmacology · 2024Review
- Bioassay-Guided Alkaloids Isolation fromMolecules (Basel, Switzerland) · 2023Article
- Identification of SARS-CoV-2 inhibitors from extracts ofSaudi journal of biological sciences · 2021Article
- Flavonoids and Terpenoids with PTP-1B Inhibitory Properties from the Infusion ofMolecules (Basel, Switzerland) · 2020Article
- Synthesis, In Vitro Evaluation and Molecular Docking of the 5-Acetyl-2-aryl-6-hydroxybenzo[Biomolecules · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Protein tyrosine phosphatase 1B (PTP1B) plays a specific role as a negative regulator of insulin signaling pathways and is a validated therapeutic target for Type 2 diabetes. Previously, arylbenzofurans were reported to have inhibitory activity against PTP1B. However, detailed investigation regarding their structure activity relationship (SAR) has not been elucidated. The main aim of this work was to investigate the PTP1B inhibitory activity of 2-arylbenzofuran analogs (sanggenofuran A (SA), mulberrofuran D2 (MD2), mulberrofuran D (MD), morusalfuran B (MB), mulberrofuran H (MH)) isolated from the root bark of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.